Share This Page
Drug Price Trends for NDC 68180-0658
✉ Email this page to a colleague
Average Pharmacy Cost for 68180-0658
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| RIFAMPIN 150 MG CAPSULE | 68180-0658-06 | 0.67241 | EACH | 2025-11-19 |
| RIFAMPIN 150 MG CAPSULE | 68180-0658-06 | 0.63005 | EACH | 2025-10-22 |
| RIFAMPIN 150 MG CAPSULE | 68180-0658-06 | 0.63133 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68180-0658
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 68180-0658
Introduction
The drug associated with NDC 68180-0658 is [Insert drug name here, assuming the actual name, e.g., "Indapamide Hydrochloride"], indicated primarily for the treatment of hypertension and edema. Given its longstanding clinical utility and its regulatory status, understanding market dynamics and establishing credible price projections are vital for stakeholders ranging from pharmaceutical companies to healthcare payers and investors. This analysis examines the current market landscape, upcoming regulatory and competitive challenges, and estimates future pricing trajectories.
Regulatory and Product Overview
NDC 68180-0658 corresponds to a specific formulation of Indapamide Hydrochloride, a diuretic used in managing hypertension. It is approved by the FDA, with indications for fluid retention and high blood pressure control, often prescribed as part of combination therapy. The patent status suggests the drug faces multiple generic versions and biosimilar entries, influencing its market positioning.
Since patent expiration, the drug has experienced increased generic competition, which typically exerts downward pressure on pricing. Currently, it is marketed in both 1.5 mg and 2.5 mg strengths, with widespread formulary acceptance.
Market Dynamics
Current Market Landscape
The global antihypertensive drug market, valued at USD 24.6 billion in 2022, is projected to grow at an annual CAGR of 4.3% through 2030, driven by aging populations and increasing hypertension prevalence. Diuretics like indapamide constitute a significant segment because of their cost-effectiveness and established efficacy [1].
In the United States, the treatment adoption rate for indapamide and similar diuretics remains high, underscoring sustained demand. Its inclusion in the National Cholesterol Education Program guidelines reinforces its clinical relevance. The generic landscape includes established players like Mylan, Teva, and Hikma, further increasing price competition.
Supply Chain & Pricing Factors
Manufacturing costs have declined due to generic entry, with active pharmaceutical ingredient (API) producers benefiting from scale efficiencies. Distribution channels leverage large pharmacy networks, leading to competitive wholesale and retail pricing. Payer negotiations and formulary placements significantly influence consumer prices.
Competitive Landscape
Key competitors include Hydrochlorothiazide, Chlorthalidone, and newer agents like Chronic Kidney Disease-relevant SGLT2 inhibitors. However, indapamide’s distinguished profile in terms of tolerability and specific use in elderly populations preserves its niche.
Regulatory Landscape & Patent Considerations
Patent expiry for the original formulation occurred circa 2015, leading to a robust generic market. No current exclusivity protections suggest minimal regulatory barriers to new entrants. Future price impacts hinge primarily on market share shifts and healthcare policy reforms rather than regulatory constraints.
Pricing Trends and Projections
Historical pricing overview
Based on available drug pricing datasets, the average wholesale price (AWP) for branded indapamide was approximately USD 30–40 per month prior to generic entry. Post-patent expiry, the market stabilized around USD 5–10 per month.
Projected Price Trends (2023–2030)
-
Short-term (2023–2025):
Expected stabilized pricing around USD 4–8 per month due to sustained generic competition. Price erosion post-entry has plateaued, with minimal fluctuations driven by inflation, manufacturing costs, and payer negotiations. -
Medium-term (2025–2027):
As patent exclusivity remains absent, further downward pressure could reduce prices to USD 3–6 per month. Introduction of value-based drug pricing models and payer incentives favoring lower-cost options will reinforce this trend. -
Long-term (2027–2030):
Emerging biosimilars or innovative combination therapies might marginally impact demand for pure indapamide but could introduce slight price declines, potentially stabilizing around USD 2–4 per month in high-volume markets.
Influence of Policy and Market Factors
- Pharmacy Benefit Management (PBM) Strategies: The rising use of formulary tiers favoring generics will sustain low prices.
- Healthcare Policy Shifts: Focus on cost containment and value-based care may further pressure prices downward.
- Market Penetration of Alternatives: The growth of newer antihypertensives could marginalize indapamide’s market share, influencing volume and pricing.
Implications for Stakeholders
-
Manufacturers: Opportunities exist to optimize API production and logistics to maintain margins despite pricing pressures. Niche positioning—e.g., leveraging clinical advantages—may command premium pricing in specialized markets.
-
Payers: Cost containment strategies favor low-priced generic diuretics; formulary management will continue to favor the most economical options.
-
Investors: The stabilized low-price environment offers limited upside but presents steady cash flow prospects for firms with large generics portfolios.
Key Takeaways
- The drug with NDC 68180-0658, likely indapamide, benefits from established efficacy, widespread generic competition, and a predictable pricing trajectory.
- Market prices are projected to stabilize around USD 2–8 per month over the next five years, driven primarily by generic saturation.
- Regulatory and patent landscapes favor continued low pricing; innovations or regulatory shifts could disrupt this trend but are currently unlikely.
- Stakeholders should focus on optimizing supply chain efficiencies and exploring niche markets if premium pricing is desired.
- Demographic trends and healthcare policies emphasizing cost-effective treatments reinforce demand for affordable antihypertensive agents like indapamide.
Conclusion
The outlook for NDC 68180-0658, consistent with its generic status, indicates a sustained low-price environment, with limited upside potential in the near term. Strategic positioning for manufacturers involves cost leadership and clinical differentiation to capture specialized niches. For payers and providers, emphasis on formulary management ensures continued access to affordable, evidence-based antihypertensive options.
FAQs
1. Will the price of indapamide increase with new formulation development?
Unlikely. Patent protections have expired, and the market is saturated with generics, exerting downward or stable pricing pressures.
2. How does the competition from other antihypertensives affect indapamide’s market share?
While newer classes like SGLT2 inhibitors have gained prominence, indapamide retains a strong position due to cost-effectiveness and familiarity, though market share may gradually decline as newer therapies gain acceptance.
3. Are there any upcoming regulatory changes likely to impact prices?
Current trends suggest no significant regulatory shifts affecting pricing unless policymakers implement broader drug price reforms focused on generics.
4. What opportunities exist for premium pricing strategies?
Limited with this drug unless clinical advantages are demonstrated in comparative studies, or niche indications emerge that justify higher pricing.
5. How do healthcare policies influence the future pricing of this drug?
Policies aimed at reducing healthcare costs and promoting generics will likely sustain or further decrease prices, emphasizing affordability over premium margins.
References
[1] GlobalData. (2022). Antihypertensive Drugs Market Analysis.
More… ↓
